Try our beta test site

Expanded Access Protocol of Patisiran for Patients With Hereditary ATTR Amyloidosis (hATTR)

Expanded access is currently available for this treatment.
Verified January 2017 by Alnylam Pharmaceuticals
Sponsor:
Information provided by (Responsible Party):
Alnylam Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT02939820
First received: October 18, 2016
Last updated: January 26, 2017
Last verified: January 2017
  Purpose
The purpose of this study is to provide expanded access of patisiran to patients with hereditary transthyretin-mediated amyloidosis (hATTR).

Condition Intervention
TTR-mediated Amyloidosis
Amyloidosis, Hereditary
Amyloid Neuropathies, Familial
Familial Amyloid Polyneuropathies
Amyloid Neuropathies
Amyloidosis, Hereditary, Transthyretin-Related
Drug: patisiran (ALN-TTR02)

Study Type: Expanded Access     What is Expanded Access?
Official Title: Expanded Access Protocol of Patisiran for Patients With Hereditary Transthyretin-Mediated Amyloidosis (hATTR Amyloidosis) With Polyneuropathy

Resource links provided by NLM:


Further study details as provided by Alnylam Pharmaceuticals:

Intervention Details:
    Drug: patisiran (ALN-TTR02)
    patisiran (ALN-TTR02) administered by intravenous (IV) infusion
Detailed Description:
Choosing to participate in an expanded access program is an important personal decision. Talk with your doctor and family members or friends about deciding to join a research study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided. For general information, see the links provided in More Information.
  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Criteria

Inclusion Criteria:

  • Male or female greater than or equal to 18 years of age
  • Have a diagnosis of hATTR
  • Meet Karnofsky performance status and Neuropathy Impairment Score (NIS) requirements
  • Have adequate complete blood counts, liver function tests and coagulation tests

Exclusion Criteria:

  • Participated in an interventional hATTR clinical trial within the last 24 months
  • Are currently eligible to participate in or currently enrolled in an ongoing interventional hATTR clinical trial
  • Have inadequate cardiac function
  • Known primary amyloidosis (AL amyloidosis) or leptomeningeal amyloidosis
  • Have known serious comorbidities or considered unfit for the program by the investigator
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02939820

Contacts
Contact: Alnylam EAP Hotline (617) 715-0200 EAP@alnylam.com

Locations
United States, Iowa
Clinical Trial Site
Iowa City, Iowa, United States
United States, Maryland
Clinical Trial Site
Baltimore, Maryland, United States
United States, Massachusetts
Clinical Trial Site
Boston, Massachusetts, United States
United States, Pennsylvania
Clinical Trial Site
Pittsburgh, Pennsylvania, United States
Sponsors and Collaborators
Alnylam Pharmaceuticals
Investigators
Study Director: Sunita Goyal, MD Alnylam Pharmaceuticals
  More Information

Additional Information:
Responsible Party: Alnylam Pharmaceuticals
ClinicalTrials.gov Identifier: NCT02939820     History of Changes
Other Study ID Numbers: ALN-TTR02-007 
Study First Received: October 18, 2016
Last Updated: January 26, 2017

Keywords provided by Alnylam Pharmaceuticals:
RNAi therapeutic
FAP
Familial Amyloid Polyneuropathies
TTR
Transthyretin
Amyloidosis

Additional relevant MeSH terms:
Amyloidosis
Polyneuropathies
Amyloid Neuropathies
Amyloid Neuropathies, Familial
Amyloidosis, Familial
Proteostasis Deficiencies
Metabolic Diseases
Peripheral Nervous System Diseases
Neuromuscular Diseases
Nervous System Diseases
Heredodegenerative Disorders, Nervous System
Neurodegenerative Diseases
Genetic Diseases, Inborn
Metabolism, Inborn Errors

ClinicalTrials.gov processed this record on March 01, 2017